Pareja, Fresia http://orcid.org/0000-0003-3748-8049
Da Cruz Paula, Arnaud
Gularte-Mérida, Rodrigo http://orcid.org/0000-0002-4383-2523
Vahdatinia, Mahsa
Li, Anqi http://orcid.org/0000-0003-1409-1858
Geyer, Felipe C.
da Silva, Edaise M. http://orcid.org/0000-0003-3281-7333
Nanjangud, Gouri
Wen, Hannah Y.
Varga, Zsuzsanna http://orcid.org/0000-0002-2855-983X
Brogi, Edi
Rakha, Emad A.
Weigelt, Britta
Reis-Filho, Jorge S. http://orcid.org/0000-0003-2969-3173
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K12 CA184746, P30CA008748, P30CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Breast Cancer Research Foundation, Cycle for survival
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 19 February 2020
Accepted: 8 May 2020
First Online: 5 June 2020
Competing interests
: J.S.R.-F. reports receiving personal/consultancy fees from Goldman Sachs and REPARE Therapeutics, membership of the scientific advisory boards of VolitionRx and Page.AI, and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech, and InVicro, outside the scope of this study. All other authors declare no conflicts of interest.